Scope of the Study
Antithrombotic drugs are used to reduce the formation of blood clots. In the normal human body, blood flows smoothly through artery and veins. If clot or thrombus occurs in arteries or veins that result in blood blockage that may lead to heart attack and stroke. This disorders collectively are the most common cause of death and disability in the developed world. Hence the demand of antithrombotic drugs creates future opportunities in the pharmaceutical industry.
The market study is being classified by Type (Anti-Coagulants, Anti-Platelet Drugs and Thrombolytic Drugs), by Application (Thromboembolic Disease Treatment, Prophylactic Treatment, Blood Clot Prevention and Hyperlipidemia Treatment) and major geographies with country level break-up.
Sanofi (France), Abbott Laboratories (United States), Bayer AG (Germany), Boehringer Ingelheim GmbH (Germany), Eli Lilly and Company (United States), Johnson & Johnson Services Inc. (United States), Pfizer Inc. (United States), Alchemia (Australia), Amneal Pharms (United States) and GlaxoSmithKline Plc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Bristol Myers Squibb Company (United States), Genentech (United States), AstraZeneca Plc. (United States), Otsuka Pharmaceutical Co. Ltd (United States) and The Medicines Company (United States).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Antithrombotic Drugs market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Antithrombotic Drugs market by Type, Application and Region.
On the basis of geography, the market of Antithrombotic Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Administration, the sub-segment i.e. Oral Route will boost the Antithrombotic Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Prevalence of Cardiovascular Diseases, Blood-Related Diseases and Rising number of Accidental Injuries
- Increased Use of Anti-Thrombotic Drugs in Aged People
- Side Effects of the Drugs like Post-Operative Bleeding
- Increasing Demand for Life Saving Drugs Due To Increasing Population
- Rising Geriatric Population Worldwide
- Growing Healthcare Infrastructure in Developing Countries
- Significant Drug Interactions
Market Leaders and their expansionary development strategies
On 03rd August 2018, Sanofi, a global biopharmaceutical company completes acquisition of Bioverativ Inc., American multinational biotechnology company.
On 25th September 2018, Health Canada approves Lovenox for the prevention of blood clot formation in the extra-corporeal circulation during hemodialysis in patients with end-stage kidney disease.
Key Target AudienceHospitals, Specialty Clinics, Ambulatory Surgical Centers and General Pharmacies
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase